IP Library › Granted Patent US 12,570,751
Granted Patent B2
US 12,570,751 · App. 17/172,698 · Granted Mar 10, 2026

Binding agents binding to PD-L1 and CD137 and use thereof

Inventors: Isil Altintas (Utrecht, NL); David Satijn (Utrecht, NL); Rik Rademaker (Utrecht, NL); Paul Parren (Odijk, NL); Ugur Sahin (Mainz, DE); Friederike Gieseke (Mainz, DE); Alexander Muik (Mainz, DE); Christian Grunwitz (Mainz, DE); Edward Van Den Brink (Utrecht, NL); Dennis Verzijl (Utrecht, NL)
Assignees: Genmab A/S; BIONTECH SE
C07K16/2878C07K16/2827C07K2317/24C07K2317/31C07K2317/33C07K2317/565C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,570,751
App. No.
17/172,698
Granted
Mar 10, 2026
Kind
B2
Abstract

The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

Claims (90)

1 . A nucleic acid or a set of nucleic acids encoding a multispecific antibody, wherein the multispecific antibody comprises:

(I) a first antigen-binding region capable of binding to human CD137, wherein said first antigen-binding region comprises a first heavy chain variable region (VH) comprising an HCDR1 sequence, an HCDR2 sequence, and an HCDR3 sequence, wherein the HCDR1 sequence comprises the amino acid sequence as set forth in SEQ ID NO: 9, the HCDR2 comprises the amino acid sequence as set forth in SEQ ID NO: 10, and the HCDR3 comprises the amino acid sequence as set forth in SEQ ID NO: 11, and wherein said first antigen-binding region further comprises a first light chain variable region (VL) comprising a LCDR1 sequence, a LCDR2 sequence, and a LCDR3 sequence, wherein the LCDR1 sequence comprises the amino acid sequence as set forth in SEQ ID NO:13, the LCDR2 sequence comprises the amino acid sequence GAS, and the LCDR3 sequence comprises the amino acid sequence set forth in SEQ ID NO:14; and

(II) a second antigen-binding region capable of binding to human PD-L1, wherein said second antigen-binding region comprises a second VH comprising an HCDR1 sequence, an HCDR2 sequence, and an HCDR3 sequence, wherein the HCDR1 sequence comprises the amino acid sequence as set forth in SEQ ID NO: 18, the HCDR2 comprises the amino acid sequence as set forth in SEQ ID NO: 19, and the HCDR3 comprises the amino acid sequence as set forth in SEQ ID NO: 20, and wherein said second antigen-binding region further comprises a second VL comprising a LCDR1 sequence, a LCDR2 sequence, and a LCDR3 sequence, wherein the LCDR1 sequence comprises the amino acid sequence as set forth in SEQ ID NO:22, the LCDR2 sequence comprises the amino acid sequence DDN, and the LCDR3 sequence comprises the amino acid sequence set forth in SEQ ID NO:23.

2 . A cell comprising the nucleic acid or set of nucleic acids according to claim 1 .

3 . A method for producing a multispecific antibody, comprising the steps of:

a) culturing a host cell producing a first antibody comprising an antigen-binding region capable of binding to human CD137 and optionally purifying said first antibody from the culture;

b) culturing a host cell producing a second antibody comprising an antigen-binding region capable of binding to human PD-L1 and optionally purifying said second antibody from the culture;

c) incubating said first antibody together with said second antibody under reducing conditions sufficient to allow the cysteines in the hinge region to undergo disulfide-bond isomerization, and

d) obtaining the multispecific antibody;

wherein the multispecific antibody comprises

(I) a first antigen-binding region capable of binding to human CD137, wherein said first antigen-binding region comprises a first heavy chain variable region (VH) comprising an HCDR1 sequence, an HCDR2 sequence, and an HCDR3 sequence, wherein the HCDR1 sequence comprises the amino acid sequence as set forth in SEQ ID NO: 9, the HCDR2 comprises the amino acid sequence as set forth in SEQ ID NO: 10, and the HCDR3 comprises the amino acid sequence as set forth in SEQ ID NO: 11, and wherein said first antigen-binding region further comprises a first light chain variable region (VL) comprising a LCDR1 sequence, a LCDR2 sequence, and a LCDR3 sequence, wherein the LCDR1 sequence comprises the amino acid sequence as set forth in SEQ ID NO:13, the LCDR2 sequence comprises the amino acid sequence GAS, and the LCDR3 sequence comprises the amino acid sequence set forth in SEQ ID NO:14; and

(II) a second antigen-binding region capable of binding to human PD-L1, wherein said second antigen-binding region comprises a second VH comprising an HCDR1 sequence, an HCDR2 sequence, and an HCDR3 sequence, wherein the HCDR1 sequence comprises the amino acid sequence as set forth in SEQ ID NO: 18, the HCDR2 comprises the amino acid sequence as set forth in SEQ ID NO: 19, and the HCDR3 comprises the amino acid sequence as set forth in SEQ ID NO: 20, and wherein said second antigen-binding region further comprises a second VL comprising a LCDR1 sequence, a LCDR2 sequence, and a LCDR3 sequence, wherein the LCDR1 sequence comprises the amino acid sequence as set forth in SEQ ID NO:22, the LCDR2 sequence comprises the amino acid sequence DDN, and the LCDR3 sequence comprises the amino acid sequence set forth in SEQ ID NO:23.

4 . The nucleic acid or set of nucleic acids according to claim 1 , wherein the second VH comprises the amino acid sequence set forth in SEQ ID NO:17.

5 . The nucleic acid or set of nucleic acids according to claim 4 , wherein the second VL comprises the amino acid sequence set forth in SEQ ID NO:21.

6 . The nucleic acid or set of nucleic acids according to claim 1 , wherein the first VH comprises the amino acid sequence set forth in SEQ ID NO:15.

7 . The nucleic acid or set of nucleic acids according to claim 1 , wherein the first VL comprises the amino acid sequence set forth in SEQ ID NO:16.

8 . The method according to claim 3 , wherein the second VH comprises the amino acid sequence set forth in SEQ ID NO:17.

9 . The method according to claim 8 , wherein the second VL comprises the amino acid sequence set forth in SEQ ID NO:21.

10 . The method according to claim 3 , wherein the first VH comprises the amino acid sequence set forth in SEQ ID NO:15.

11 . The method according to claim 3 , wherein the first VL comprises the amino acid sequence set forth in SEQ ID NO:16.

12 . The method according to claim 3 , wherein the first antigen binding region further comprises a first heavy chain constant region (CH), wherein in said first CH at least one of the amino acids in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain according to EU numbering has been substituted, and wherein the second antigen binding region further comprises a second CH, wherein in said second CH at least one of the amino acids in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain according to EU numbering has been substituted, and wherein said first CH and said second CH are not substituted in the same positions.

13 . The method according to claim 12 , wherein

(i) the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said first CH, and the amino acid the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said second CH;

or

(ii) the amino acid the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said first CH and the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said second CH.

14 . The method according to claim 12 , wherein in at least one of said first CH and said second CH one or more amino acids in the positions corresponding to positions L234, L235, D265, N297, and P331 in a human IgG1 heavy chain according to EU numbering, are not L, L, D, N, and P, respectively.

15 . The method according to claim 14 , wherein the positions corresponding to positions L234, L235 and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively, in said first CH and said second CH.

16 . A nucleic acid or set of nucleic acids encoding a multispecific antibody comprising,

(I) a first antigen-binding region capable of binding to human CD137, wherein said first antigen-binding region comprises a first heavy chain variable region (VH) comprising an HCDR1 sequence, an HCDR2 sequence, and an HCDR3 sequence, wherein the HCDR1 sequence comprises the amino acid sequence as set forth in SEQ ID NO: 9, the HCDR2 comprises the amino acid sequence as set forth in SEQ ID NO: 10, and the HCDR3 comprises the amino acid sequence as set forth in SEQ ID NO: 11, and wherein said first antigen-binding region further comprises a first light chain variable region (VL) comprising a LCDR1 sequence, a LCDR2 sequence, and a LCDR3 sequence, wherein the LCDR1 sequence comprises the amino acid sequence as set forth in SEQ ID NO:13, the LCDR2 sequence comprises the amino acid sequence GAS, and the LCDR3 sequence comprises the amino acid sequence set forth in SEQ ID NO:14;

wherein the first antigen binding region further comprises a first heavy chain constant region (CH), wherein in said first CH at least one of the amino acids in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain according to EU numbering has been substituted; and

(II) a second antigen-binding region capable of binding to human PD-L1, wherein said second antigen-binding region comprises a second VH comprising an HCDR1 sequence, an HCDR2 sequence, and an HCDR3 sequence, wherein the HCDR1 sequence comprises the amino acid sequence as set forth in SEQ ID NO: 18, the HCDR2 comprises the amino acid sequence as set forth in SEQ ID NO: 19, and the HCDR3 comprises the amino acid sequence as set forth in SEQ ID NO: 20, and wherein said second antigen-binding region further comprises a second VL comprising a LCDR1 sequence, a LCDR2 sequence, and a LCDR3 sequence, wherein the LCDR1 sequence comprises the amino acid sequence as set forth in SEQ ID NO:22, the LCDR2 sequence comprises the amino acid sequence DDN, and the LCDR3 sequence comprises the amino acid sequence set forth in SEQ ID NO:23;

wherein the second antigen binding region further comprises a second CH, wherein in said second CH at least one of the amino acids in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain according to EU numbering has been substituted, and wherein said first CH and said second CH are not substituted in the same positions.

17 . The nucleic acid or set of nucleic acids according to claim 16 , wherein

(i) the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said first CH, and the amino acid in the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said second CH;

or

(ii) the amino acid in the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said first CH and the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said second CH.

18 . The nucleic acid or set of nucleic acids according to claim 16 , wherein in at least one of said first CH and second CH one or more amino acids in the positions corresponding to positions L234, L235, D265, N297, and P331 in a human IgG1 heavy chain according to EU numbering, are not L, L, D, N, and P, respectively.

19 . The nucleic acid or set of nucleic acids according to claim 18 , wherein the position corresponding to positions L234, L235 and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively, in said first CH and said second CH.

20 . A cell comprising the nucleic acid or set of nucleic acids according to claim 16 .

21 . The nucleic acid or set of nucleic acids according to claim 16 , wherein the first VH comprises the amino acid sequence set forth in SEQ ID NO:15.

22 . The nucleic acid or set of nucleic acids according to claim 16 , wherein the first VL comprises the amino acid sequence set forth in SEQ ID NO:16.

23 . The nucleic acid or set of nucleic acids according to claim 16 , wherein the second VH comprises the amino acid sequence set forth in SEQ ID NO:17.

24 . The nucleic acid or set of nucleic acids according to claim 23 , wherein the second VL comprises the amino acid sequence set forth in SEQ ID NO:21.

25 . The nucleic acid or set of nucleic acids of claim 16 , wherein the first VH comprises the amino acid sequence set forth in SEQ ID NO:15, wherein the first VL comprises the amino acid sequence set forth in SEQ ID NO:16, wherein the second VH comprises the amino acid sequence set forth in SEQ ID NO:17, wherein the second VL comprises the amino acid sequence set forth in SEQ ID NO:21, and wherein

(i) the first CH comprises an amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 24 and the second CH comprises an amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 25; or

(ii) the first CH comprises an amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 25 and the second CH comprises an amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 24.

26 . The nucleic acid or set of nucleic acids of claim 25 , wherein

(i) the first CH comprises the amino acid sequence set forth in SEQ ID NO: 24 and the second CH comprises the amino acid sequence set forth in SEQ ID NO: 25; or

(ii) the first CH comprises the amino acid sequence set forth in SEQ ID NO: 25 and the second CH comprises the amino acid sequence set forth in SEQ ID NO: 24.

27 . A nucleic acid or a set of nucleic acids encoding a multispecific antibody, wherein the multispecific antibody comprises (I) a first antigen-binding region capable of binding to human CD137, and (II) a second antigen-binding region capable of binding to human PD-L1,

wherein the first antigen-binding region comprises a first heavy chain variable region (VH) and a first light chain variable region (VL);

wherein said second antigen-binding region comprises a second VH comprising an HCDR1 sequence, an HCDR2 sequence, and an HCDR3 sequence, wherein the HCDR1 sequence comprises the amino acid sequence as set forth in SEQ ID NO: 18, the HCDR2 comprises the amino acid sequence as set forth in SEQ ID NO: 19, and the HCDR3 comprises the amino acid sequence as set forth in SEQ ID NO: 20, and

wherein said second antigen-binding region further comprises a second VL comprising a LCDR1 sequence, a LCDR2 sequence, and a LCDR3 sequence, wherein the LCDR1 sequence comprises the amino acid sequence as set forth in SEQ ID NO:22, the LCDR2 sequence comprises the amino acid sequence DDN, and the LCDR3 sequence comprises the amino acid sequence set forth in SEQ ID NO:23.

28 . The nucleic acid or set of nucleic acids according to claim 27 , wherein the second VH comprises the amino acid sequence set forth in SEQ ID NO:17.

29 . The nucleic acid or set of nucleic acids according to claim 27 , wherein the second VL comprises the amino acid sequence set forth in SEQ ID NO:21.

30 . The nucleic acid or set of nucleic acids according to claim 27 , wherein the first antigen binding region comprises a first heavy chain constant region (CH), wherein in said first CH at least one of the amino acids in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain according to EU numbering has been substituted, and wherein the second antigen binding region further comprises a second CH, wherein in said second CH at least one of the amino acids in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain according to EU numbering has been substituted, and wherein said first CH and said second CH are not substituted in the same positions.

31 . The nucleic acid or set of nucleic acids according to claim 30 , wherein

(i) the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said first CH, and the amino acid in the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said second CH; or

(ii) the amino acid in the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said first CH and the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said second CH.

32 . The nucleic acid or set of nucleic acids according to claim 30 , wherein in at least one of said first CH and said second CH one or more amino acids in the positions corresponding to positions L234, L235, D265, N297, and P331 in a human IgG1 heavy chain according to EU numbering, are not L, L, D, N, and P, respectively.

33 . The nucleic acid or set of nucleic acids according to claim 32 , wherein the position corresponding to positions L234, L235 and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively, in said first CH and said second CH.

34 . A cell comprising the nucleic acid or set of nucleic acids according to claim 27 .

35 . A method for producing a multispecific antibody, comprising the steps of:

a) culturing a host cell producing a first antibody comprising an antigen-binding region capable of binding to human CD137 and optionally purifying said first antibody from the culture;

b) culturing a host cell producing a second antibody comprising an antigen-binding region capable of binding to human PD-L1 and optionally purifying said second antibody from the culture;

c) incubating said first antibody together with said second antibody under reducing conditions sufficient to allow the cysteines in the hinge region to undergo disulfide-bond isomerization, and

d) obtaining the multispecific antibody;

wherein the multispecific antibody comprises

(I) a first antigen-binding region capable of binding to human CD137, wherein the first antigen-binding region comprises a first heavy chain variable region (VH) and a first light chain variable region (VL);

(II) a second antigen-binding region capable of binding to human PD-L1, wherein said second antigen-binding region capable of binding to human PD-L1 comprises a second VH comprising an HCDR1 sequence, an HCDR2 sequence, and an HCDR3 sequence, wherein the HCDR1 sequence comprises the amino acid sequence as set forth in SEQ ID NO: 18, the HCDR2 comprises the amino acid sequence as set forth in SEQ ID NO: 19, and the HCDR3 comprises the amino acid sequence as set forth in SEQ ID NO: 20, and

wherein said second antigen-binding region further comprises a second VL comprising a LCDR1 sequence, a LCDR2 sequence, and a LCDR3 sequence, wherein the LCDR1 sequence comprises the amino acid sequence as set forth in SEQ ID NO:22, the LCDR2 sequence comprises the amino acid sequence DDN, and the LCDR3 sequence comprises the amino acid sequence set forth in SEQ ID NO:23.

36 . The method according to claim 35 , wherein the second VH comprises the amino acid sequence set forth in SEQ ID NO:17.

37 . The method according to claim 35 , wherein the second VL comprises the amino acid sequence set forth in SEQ ID NO:21.

38 . The method according to claim 35 , wherein the first antigen binding region comprises a first heavy chain constant region (CH), wherein in said first CH at least one of the amino acids in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain according to EU numbering has been substituted, and wherein the second antigen binding region comprises a second CH, wherein in said second CH at least one of the amino acids in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407, and K409 in a human IgG1 heavy chain according to EU numbering has been substituted, and wherein said first CH and said second CH are not substituted in the same positions.

39 . The method according to claim 38 , wherein

(i) the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said first CH, and the amino acid the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said second CH;

or

(ii) the amino acid the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said first CH and the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said second CH.

40 . The method according to claim 38 , wherein in at least one of said first CH and said second CH one or more amino acids in the positions corresponding to positions L234, L235, D265, N297, and P331 in a human IgG1 heavy chain according to EU numbering, are not L, L, D, N, and P, respectively.

41 . The method according to claim 38 , wherein the position corresponding to positions L234, L235 and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively, in said first CH and said second CH.

42 . The method of claim 35 , wherein the first VH comprises the amino acid sequence set forth in SEQ ID NO:15, wherein the first VL comprises the amino acid sequence set forth in SEQ ID NO:16, wherein the second VH comprises the amino acid sequence set forth in SEQ ID NO:17, wherein the second VL comprises the amino acid sequence set forth in SEQ ID NO:21, and wherein

(i) the first antigen binding region further comprises a first heavy chain constant region (CH), wherein the first CH comprises an amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 24 and the second antigen binding region further comprises a second CH, wherein the second CH comprises an amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 25;

or

(ii) the first CH comprises an amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 25 and the second CH comprises an amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 24.

43 . The method of claim 42 , wherein (i) the first CH comprises the amino acid sequence set forth in SEQ ID NO: 24 and the second CH comprises the amino acid sequence set forth in SEQ ID NO: 25, or (ii) the first CH comprises the amino acid sequence set forth in SEQ ID NO: 25 and the second CH comprises the amino acid sequence set forth in SEQ ID NO: 24.

44 . The method according to claim 13 , wherein the position corresponding to positions L234, L235 and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively, in said first CH and said second CH.

45 . The nucleic acid or set of nucleic acids according to claim 17 , wherein the position corresponding to positions L234, L235 and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively, in said first CH and said second CH.

46 . The nucleic acid or set of nucleic acids according to claim 1 , wherein the first antigen-binding region further comprises a first heavy chain constant region (CH) and wherein second antigen-binding region further comprises a second CH, wherein in said first CH and said second CH the position corresponding to positions L234, L235 and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively, and wherein

(i) the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said first CH, and the amino acid in the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said second CH, or

(ii) the amino acid in the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said first CH and the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said second CH.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2026
From: BIONTECH SE
To: GENMAB A/S
Reel/Frame 074463/0678 →
CHANGE OF ADDRESS Recorded Feb 13, 2024
From: GENMAB A/S
To: GENMAB A/S
Reel/Frame 066570/0587 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2022
From: ALTINTAS, ISIL; SATIJN, DAVID; RADEMAKER, RIK; PARREN, PAUL
To: GENMAB A/S
Reel/Frame 060892/0605 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2022
From: SAHIN, UGUR; GIESEKE, FRIEDERIKE; MUIK, ALEXANDER; GRUNWITZ, CHRISTIAN
To: BIONTECH AG
Reel/Frame 060892/0614 →
CHANGE OF NAME Recorded Aug 24, 2022
From: BIONTECH AG
To: BIONTECH SE
Reel/Frame 061314/0036 →
Priority Claims (2)
WO PCT/EP2017/069839 · Aug 4, 2017 · international
WO PCT/EP2018/052946 · Feb 6, 2018 · international
Continuity (3)
Division 16779011 · Jan 31, 2020
Continuation PCTEP2018071002 · Aug 2, 2018
Related Publication 20210269541A1 · Sep 2, 2021
References Cited (400)
US 4474893A · Reading · 1984 [cited by applicant]
US 4714681A · Reading · 1987 [cited by applicant]
US 4925648A · Hansen et al. · 1990 [cited by applicant]
US 5475096A · Gold · 1995 [cited by applicant]
US 5573920A · Randle · 1996 [cited by applicant]
US 5589466A · Felgner et al. · 1996 [cited by applicant]
US 5601819A · Wong et al. · 1997 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5973972A · Kwon et al. · 1999 [cited by applicant]
US 6077835A · Hanson et al. · 2000 [cited by applicant]
US 6808710B1 · Wood · 2004 [cited by applicant]
US 7262028B2 · Van Berkel et al. · 2007 [cited by applicant]
US 7488802B2 · Collins · 2009 [cited by applicant]
US 7612181B2 · Wu et al. · 2009 [cited by applicant]
US 7951918B2 · Glaser et al. · 2011 [cited by applicant]
US 8008449B2 · Korman et al. · 2011 [cited by applicant]
US 8168757B2 · Finnefrock · 2012 [cited by applicant]
US 8354509B2 · Carven et al. · 2013 [cited by applicant]
US 8735553B1 · Li · 2014 [cited by applicant]
US 8779105B2 · Korman · 2014 [cited by applicant]
US 8779108B2 · Queva · 2014 [cited by applicant]
US 9834606B2 · Li et al. · 2017 [cited by applicant]
US 10882913B2 · Overdijk et al. · 2021 [cited by applicant]
US 10968280B2 · Altintas · 2021 [cited by applicant]
US 11084882B2 · Altintas · 2021 [cited by applicant]
US 11091557B2 · Altintas · 2021 [cited by applicant]
US 11440966B2 · Altintas · 2022 [cited by applicant]
US 11459395B2 · Altintas · 2022 [cited by applicant]
US 11549395B2 · Nayak et al. · 2023 [cited by applicant]
US 11939388B2 · Altintas · 2024 [cited by applicant]
US 12077596B2 · Altintas · 2024 [cited by applicant]
US 20030118588A1 · Diehl et al. · 2003 [cited by applicant]
US 20030223989A1 · Pluenneke · 2003 [cited by applicant]
US 20060088523A1 · Andya · 2006 [cited by applicant]
US 20080008716A1 · Kwon · 2008 [cited by applicant]
US 20090074711A1 · Martin · 2009 [cited by applicant]
US 20100155133A1 · Makwinski et al. · 2010 [cited by applicant]
US 20100226923A1 · Rao et al. · 2010 [cited by applicant]
US 20100303811A1 · Ochi · 2010 [cited by applicant]
US 20110223188A1 · Langermann · 2011 [cited by applicant]
US 20110311550A1 · Law · 2011 [cited by applicant]
US 20130039911A1 · Bedi · 2013 [cited by applicant]
US 20140099254A1 · Chang · 2014 [cited by applicant]
US 20140170148A1 · De Goeij · 2014 [cited by applicant]
US 20140341917A1 · Nastri · 2014 [cited by applicant]
US 20140348839A1 · Chowdhur · 2014 [cited by applicant]
US 20150079109A1 · Li · 2015 [cited by applicant]
US 20150175707A1 · De Jong · 2015 [cited by applicant]
US 20150203579A1 · Papadopoulos · 2015 [cited by applicant]
US 20160244528A1 · Gray · 2016 [cited by applicant]
US 20160256527A1 · Gurney · 2016 [cited by applicant]
US 20160257752A1 · Jeong et al. · 2016 [cited by applicant]
US 20160272708A1 · Chen · 2016 [cited by applicant]
US 20160376367A1 · Yuan et al. · 2016 [cited by applicant]
US 20170198050A1 · Eckleman et al. · 2017 [cited by applicant]
US 20170210806A1 · Liu · 2017 [cited by applicant]
US 20170226217A1 · Ellmark · 2017 [cited by applicant]
US 20170334995A1 · Zettl et al. · 2017 [cited by applicant]
US 20180185482A1 · Sheng · 2018 [cited by applicant]
US 20200062853A1 · Altintas · 2020 [cited by applicant]
US 20200165349A1 · Altintas · 2020 [cited by applicant]
US 20200190191A1 · Campbell et al. · 2020 [cited by applicant]
US 20200197396A1 · Withana · 2020 [cited by applicant]
US 20200239579A1 · Altintas · 2020 [cited by applicant]
US 20200247899A1 · Altintas · 2020 [cited by applicant]
US 20200332015A1 · Gunde et al. · 2020 [cited by applicant]
US 20210163616A1 · Altintas · 2021 [cited by applicant]
US 20210269541A1 · Altintas · 2021 [cited by applicant]
US 20210277133A1 · Altintas · 2021 [cited by applicant]
US 20210317225A1 · Altintas · 2021 [cited by applicant]
US 20210369842A1 · Altintas · 2021 [cited by applicant]
US 20220033510A1 · Altintas · 2022 [cited by applicant]
US 20220064317A1 · Altintas · 2022 [cited by applicant]
US 20230087164A1 · Sahin et al. · 2023 [cited by applicant]
US 20230087745A1 · Altintas · 2023 [cited by applicant]
US 20230089969A1 · Altintas · 2023 [cited by applicant]
US 20240109972A1 · Sahin et al. · 2024 [cited by applicant]
US 20240262924A1 · Sahin et al. · 2024 [cited by applicant]
US 20240317861A1 · Altintas · 2024 [cited by applicant]
US 20250002600A1 · Muik et al. · 2025 [cited by applicant]
AU 2004279877A1 · 2005 [cited by applicant]
AU 2004279877B2 · 2010 [cited by applicant]
CN 101023102A · 2007 [cited by applicant]
CN 102250246A · 2011 [cited by applicant]
CN 104994873A · 2015 [cited by applicant]
CN 105669862A · 2016 [cited by applicant]
CN 107840887A · 2018 [cited by applicant]
EP 0629240A1 · 1994 [cited by applicant]
EP 0629240B1 · 2002 [cited by applicant]
EP 1870459A1 · 2007 [cited by applicant]
EP 1975182A1 · 2008 [cited by applicant]
EP 2270051A2 · 2011 [cited by applicant]
EP 3050963A1 · 2016 [cited by applicant]
JP 2016533335A · 2016 [cited by applicant]
JP 2018513159A · 2018 [cited by applicant]
RU 2464276C2 · 2012 [cited by applicant]
WO WO1991000360A1 · 1991 [cited by applicant]
WO WO1992005793A1 · 1992 [cited by applicant]
WO WO1992008802A1 · 1992 [cited by applicant]
WO WO1992022653A1 · 1992 [cited by applicant]
WO WO1993017715A1 · 1993 [cited by applicant]
WO WO1998050431A2 · 1998 [cited by applicant]
WO WO1999036093A1 · 1999 [cited by applicant]
WO WO2000046147A2 · 2000 [cited by applicant]
WO WO2000070087A1 · 2000 [cited by applicant]
WO WO2002020039A2 · 2002 [cited by applicant]
WO WO2002028481A2 · 2002 [cited by applicant]
WO WO2003040170A2 · 2003 [cited by applicant]
WO WO2003042402A2 · 2003 [cited by applicant]
WO WO2003074569A2 · 2003 [cited by applicant]
WO WO2003080672A1 · 2003 [cited by applicant]
WO WO2003099196A2 · 2003 [cited by applicant]
WO WO2004004771A1 · 2004 [cited by applicant]
WO WO2005004809A2 · 2005 [cited by applicant]
WO WO2005035584A1 · 2005 [cited by applicant]
WO WO2005044307A2 · 2005 [cited by applicant]
WO WO2005044854A2 · 2005 [cited by applicant]
WO WO2005044855A2 · 2005 [cited by applicant]
WO WO2005061547A2 · 2005 [cited by applicant]
WO WO2005092927A1 · 2005 [cited by applicant]
WO WO2006044908A2 · 2006 [cited by applicant]
WO WO2006121168A1 · 2006 [cited by applicant]
WO WO2007053767A1 · 2007 [cited by applicant]
WO WO2007059782A1 · 2007 [cited by applicant]
WO WO2007110205A2 · 2007 [cited by applicant]
WO WO2007005874A2 · 2007 [cited by applicant]
WO WO2008003116A2 · 2008 [cited by applicant]
WO WO2008051424A2 · 2008 [cited by applicant]
WO WO2008119353A1 · 2008 [cited by applicant]
WO WO2008156712A1 · 2008 [cited by applicant]
WO WO2008157379A2 · 2008 [cited by applicant]
WO WO2009014708A2 · 2009 [cited by applicant]
WO WO2009034172A1 · 2009 [cited by applicant]
WO WO2009040562A1 · 2009 [cited by applicant]
WO WO2009058383A2 · 2009 [cited by applicant]
WO WO2009080251A1 · 2009 [cited by applicant]
WO WO2009080252A1 · 2009 [cited by applicant]
WO WO2009080253A1 · 2009 [cited by applicant]
WO WO2009080254A1 · 2009 [cited by applicant]
WO WO2009089004A1 · 2009 [cited by applicant]
WO WO2009101611A1 · 2009 [cited by applicant]
WO WO2009114335A2 · 2009 [cited by applicant]
WO WO2010015792A1 · 2010 [cited by applicant]
WO WO2010026923A1 · 2010 [cited by applicant]
WO WO2010027827A2 · 2010 [cited by applicant]
WO WO2010036959A2 · 2010 [cited by applicant]
WO WO2010059315A1 · 2010 [cited by applicant]
WO WO2010077634A1 · 2010 [cited by applicant]
WO WO2010080538A1 · 2010 [cited by applicant]
WO WO2010089411A2 · 2010 [cited by applicant]
WO WO2010111625A1 · 2010 [cited by applicant]
WO WO2010129304A2 · 2010 [cited by applicant]
WO WO2010134666A1 · 2010 [cited by applicant]
WO WO2010151792A1 · 2010 [cited by applicant]
WO WO2011028952A1 · 2011 [cited by applicant]
WO WO2011066342A2 · 2011 [cited by applicant]
WO WO2011066389A1 · 2011 [cited by applicant]
WO WO2011066501A1 · 2011 [cited by applicant]
WO WO2011069104A2 · 2011 [cited by applicant]
WO WO2011082400A2 · 2011 [cited by applicant]
WO WO2011104558A1 · 2011 [cited by applicant]
WO WO2011117329A1 · 2011 [cited by applicant]
WO WO2011131746A2 · 2011 [cited by applicant]
WO WO2011143545A1 · 2011 [cited by applicant]
WO WO2011159877A2 · 2011 [cited by applicant]
WO WO2011161699A2 · 2011 [cited by applicant]
WO WO2012023053A2 · 2012 [cited by applicant]
WO WO2012025525A1 · 2012 [cited by applicant]
WO WO2012025530A1 · 2012 [cited by applicant]
WO WO2012032433A1 · 2012 [cited by applicant]
WO WO2012058768A1 · 2012 [cited by applicant]
WO WO2012145183A2 · 2012 [cited by applicant]
WO WO2012145493A1 · 2012 [cited by applicant]
WO WO2012149356A2 · 2012 [cited by applicant]
WO WO2013004842A2 · 2013 [cited by applicant]
WO WO2013060867A2 · 2013 [cited by applicant]
WO WO2013079174A1 · 2013 [cited by applicant]
WO WO2013157953A1 · 2013 [cited by applicant]
WO WO2013164694A1 · 2013 [cited by applicant]
WO WO2013173223A1 · 2013 [cited by applicant]
WO WO2014022758A1 · 2014 [cited by applicant]
WO WO2014055648A1 · 2014 [cited by applicant]
WO WO2014070934A1 · 2014 [cited by applicant]
WO WO2014081202A1 · 2014 [cited by applicant]
WO WO2014100079A1 · 2014 [cited by applicant]
WO WO2014108483A1 · 2014 [cited by applicant]
WO WO2014148895A1 · 2014 [cited by applicant]
WO WO2014179664A2 · 2014 [cited by applicant]
WO WO2014194302A2 · 2014 [cited by applicant]
WO WO2015001085A1 · 2015 [cited by applicant]
WO WO2017009442A1 · 2015 [cited by applicant]
WO WO2015035606A1 · 2015 [cited by applicant]
WO WO2015048520A1 · 2015 [cited by applicant]
WO WO2015085847A1 · 2015 [cited by applicant]
WO WO2015112800A1 · 2015 [cited by applicant]
WO WO2015112900A1 · 2015 [cited by applicant]
WO WO2015150327A1 · 2015 [cited by applicant]
WO WO2015156268A1 · 2015 [cited by applicant]
WO WO2015179236A1 · 2015 [cited by applicant]
WO WO2016061142A1 · 2016 [cited by applicant]
WO WO2016097300A1 · 2016 [cited by applicant]
WO WO2016100882A1 · 2016 [cited by applicant]
WO WO2016110576A1 · 2016 [cited by applicant]
WO WO2016110584A1 · 2016 [cited by applicant]
WO WO2016134358A1 · 2016 [cited by applicant]
WO WO2016168716A1 · 2016 [cited by applicant]
WO WO2016185016A1 · 2016 [cited by applicant]
WO WO2017019846A1 · 2017 [cited by applicant]
WO WO2017024465A1 · 2017 [cited by applicant]
WO WO2017025016A1 · 2017 [cited by applicant]
WO WO2017025051A1 · 2017 [cited by applicant]
WO WO2017040790A1 · 2017 [cited by applicant]
WO WO2017049452A1 · 2017 [cited by applicant]
WO WO2017055398A2 · 2017 [cited by applicant]
WO WO2017055547A1 · 2017 [cited by applicant]
WO WO2017060144A1 · 2017 [cited by applicant]
WO WO2017071625A1 · 2017 [cited by applicant]
WO WO2017077085A2 · 2017 [cited by applicant]
WO WO2017106656A1 · 2017 [cited by applicant]
WO WO2017123650A2 · 2017 [cited by applicant]
WO WO2017132825A1 · 2017 [cited by applicant]
WO WO2017133540A1 · 2017 [cited by applicant]
WO WO2017166804A1 · 2017 [cited by applicant]
WO WO2017182672A1 · 2017 [cited by applicant]
WO WO2017201281A1 · 2017 [cited by applicant]
WO WO2017205738A1 · 2017 [cited by applicant]
WO WO2017209053A1 · 2017 [cited by applicant]
WO WO2017214092A1 · 2017 [cited by applicant]
WO WO2017218707A2 · 2017 [cited by applicant]
WO WO2018011421A1 · 2018 [cited by applicant]
WO WO2018014260A1 · 2018 [cited by applicant]
WO WO2018017761A1 · 2018 [cited by applicant]
WO WO2018022831A1 · 2018 [cited by applicant]
WO WO2018036472A1 · 2018 [cited by applicant]
WO WO2018056821A1 · 2018 [cited by applicant]
WO WO2018098370A1 · 2018 [cited by applicant]
WO WO2018103017A1 · 2018 [cited by applicant]
WO WO2018103501A1 · 2018 [cited by applicant]
WO WO2018162749A1 · 2018 [cited by applicant]
WO WO2018187215A1 · 2018 [cited by applicant]
WO WO2018213747A1 · 2018 [cited by applicant]
WO WO2018222711A2 · 2018 [cited by applicant]
WO WO2019000146A1 · 2019 [cited by applicant]
WO WO2019025545A1 · 2019 [cited by applicant]
WO WO2020011964A1 · 2020 [cited by applicant]
WO WO2020018354A1 · 2020 [cited by applicant]
WO WO2020094744A1 · 2020 [cited by applicant]
WO WO2020107715A1 · 2020 [cited by applicant]
WO WO2020197396A1 · 2020 [cited by applicant]
WO WO2020263879A1 · 2020 [cited by applicant]
WO WO2021084104A1 · 2021 [cited by applicant]
WO WO2021113307A2 · 2021 [cited by applicant]
WO WO2021113307A3 · 2021 [cited by applicant]
WO WO2021156258A1 · 2021 [cited by applicant]
WO WO2021156326A1 · 2021 [cited by applicant]
WO WO2021167885A1 · 2021 [cited by applicant]
WO WO2022189498A1 · 2022 [cited by applicant]
WO WO2023285552A1 · 2023 [cited by applicant]
Lloyd et al (Protein Engineering, Design & Selection, 22:159-168, 2009). [cited by examiner]
Edwards et al (J Mol Biol, 14;334(1):103-118, 2003). [cited by examiner]
Almagro & Fransson, Frontiers in Bioscience 2008; 13:1619-33. [cited by examiner]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/EP2018/055977, mailed Jul. 4, 2018. [cited by applicant]
Canfield et al., “The Binding Affinity of Human IgG for its High Affinity Fc Receptor Is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region”, J. Exp. Med., 1991, (173): 1483-1491. [cited by applicant]
Chen et al., Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), J Clin Oncol, 2017, 35(15 suppl): abstr TPS7575. [cited by applicant]
ClinicalTrials.gov, Clinical Trial NCT02554812, “A Study of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)”, Sep. 18, 2015. [cited by applicant]
Colman et al., “Effects of amino acid sequence changes on antibody-antigen interactions”, Research in Immunology, 1994, 145: 33-36. [cited by applicant]
Dall'Acqua et al., “Modulation of the Effector Functions of a Human IgG1 through Engineering of Its Hinge Region”, J Immunol., 2006, 177(2): 1129-1138. [cited by applicant]
Dondelinger et al., “Understanding the significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition”, Fronti15.ers in Immunology, Oct. 16, 2018, vol. 9, Article 2278, pp. 1-15. [cited by applicant]
Duncan et al., “The Binding Site for Clq on IgG”, Nature, 1988 (332): 738-740. [cited by applicant]
Hezareh et al., “Effector Function Activities of a Panel of Mutant of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1”, J Virol., 2001, 75(24): 12161-12168. [cited by applicant]
Horton et al., “Agonist anti-4-1BB plus neutralizing anti-CTLA-4 or -PD-L1 synergize to promote tumor regression by rescuing dying dysfunctional CD8+ T cells within the tumor microenvironment”, J Immunother Cancer, 2015… [cited by applicant]
Idusogie et al., “Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc”, J Immunol., 2000, 164: 4178-4184. [cited by applicant]
International Search Report and Written Opinion in related PCT Application No. PCT/EP2018/071002, mailed Jan. 4, 2019 (18 pages). [cited by applicant]
Leabman et al., “Effects of Altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys”, MAbs, 2013, 5(6): 896-903. [cited by applicant]
Oganesyan et al., “Structural characterization of a human Fc fragment engineered for lack of effector functions”, Acta Cryst., 2008, (D64): 700-704. [cited by applicant]
Paul et al., Fundamental Immunology, Third Edition, 1993, Chapter 9, pp. 292-295. [cited by applicant]
Ramelet et al., “Beneficial outcome of combination therapy with 4-1BB targeting antibody”, European Journal of Cancer, vol. 69, Nov. 29, 2016. [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity”, Proc. Natl Acad. Sci. USA, 1982, 79: 1979-1983, Immunology. [cited by applicant]
Shields et al., “High Resolution Mapping of the Binding Site on Human OgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR*”, J. Biol. Chem., 2001, 276(9): 6591-6604. [cited by applicant]
Shindo et al., “Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor”, Anticancer Research—International Journal of Cancer Research and Tre… [cited by applicant]
Storz, “Intellectual property issues of immune checkpoint inhibitors”, mAbs, 2016, 8(1): 10-26. [cited by applicant]
Xu et al., “In Vitro Characterization of Five Humanized OKT3 Effector Function Variant Antibodies”, Cell Immunol., 2000, 200: 16-26. [cited by applicant]
Barthelemy, “Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains”, Journal of Biological Chemistry, 2008, 283:3639-3654. [cited by applicant]
Beiboer et al., “Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent”, Journal of Molecul… [cited by applicant]
Choi et al., “Predicting antibody complementarity determining region structures without classification”, Molecular Biosystems, 2011, 7:3327-334. [cited by applicant]
De Genst et al., “Antibody repertoire development in camelids”, Developmental and Comparative Immunology, 30 (2006); 187-198. [cited by applicant]
Griffiths et al., “Human anti-self antibodies with high specificity from phage display libraries”, The EMBO Journal, 1993, 12:725-734. [cited by applicant]
Klimka et al., “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning”, British Journal of Cancer, 2000, 83:252-260. [cited by applicant]
Malia et al., “Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8”, Proteins, 2016, 84: 427-434. [cited by applicant]
Ward et al., Binding activities of a repertoire of single immunoglobin variable domains secreted from [cited by applicant]
U.S. Appl. No. 16/491,464 2020/0239579, filed Sep. 5, 2019 Jul. 30, 2020, Isil Altintas. [cited by applicant]
PCT/EP2018/071002 WO 2020/030580, Aug. 2, 2018 Feb. 13, 2020, Isil Altintas. [cited by applicant]
U.S. Appl. No. 16/779,011 2020/0165349 U.S. Pat. No. 10,968,280, filed Jan. 31, 2020 May 28, 2020 Apr. 6, 2021, Isil Altintas. [cited by applicant]
U.S. Appl. No. 17/172,694 2021/0163616, filed Feb. 10, 2021 Jun. 3, 2021, Isil Altintas. [cited by applicant]
U.S. Appl. No. 17/172,700, filed Feb. 10, 2021, Isil Altintas. [cited by applicant]
U.S. Appl. No. 17/172,694 2021/0163616 U.S. Pat. No. 11,459,395, filed Feb. 10, 2021 Jun. 3, 2021 Sep. 14, 2022, Isil Altintas. [cited by applicant]
U.S. Appl. No. 17/821,837, filed Aug. 24, 2022, Isil Altintas. [cited by applicant]
U.S. Appl. No. 17/172,700 2021/0277133, filed Feb. 10, 2021 Sep. 9, 2021, Isil Altintas. [cited by applicant]
U.S. Appl. No. 16/491,464 2020/0239579, filed Sep. 5, 2019 Jul. 30, 2020, Isil Altintas, Antibodies Against PD-L1. [cited by applicant]
U.S. Appl. No. 18/539,509 2024/0317861, filed Dec. 14, 2023 Sep. 26, 2024, Isil Altintas, Antibodies Against PD-L1. [cited by applicant]
U.S. Appl. No. 16/779,011 2020/0165349 U.S. Pat. No. 10,968,280, filed Jan. 31, 2020 May 28, 2020 Apr. 6, 2021, Isil Altintas, Binding Agents Binding To PD-L1 and CD137 and Use Thereof. [cited by applicant]
U.S. Appl. No. 17/172,694 2021/0163616 U.S. Pat. No. 11,459,395, filed Feb. 10, 2021 Jun. 3, 2021 Sep. 14, 2022, Isil Altintas, Binding Agents Binding To PD-L1 and CD137 and Use Thereof. [cited by applicant]
U.S. Appl. No. 17/821,837 2023/0087745, filed Aug. 24, 2022 Mar. 23, 2023, Isil Altintas, Binding Agents Binding To PD-L1 and CD137 and Use Thereof. [cited by applicant]
U.S. Appl. No. 17/172,700 2021/0277133, filed Feb. 10, 2021 Sep. 9, 2021, Isil Altintas, Binding Agents Binding To PD-L1 and CD137 and Use Thereof. [cited by applicant]
Brekke et al., The structural requirements for complement activation by IgG: does it hinge on the hinge?, Immunology Today, Feb. 1995, 16(2): 85-90. [cited by applicant]
Brown et al., Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?, J. Immunol, May 1, 1996, 156(9): 3285-3291. [cited by applicant]
Chu et al., An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer, Int. Journal of Molecular Sciences, Apr. 12, 2019, 20(8): 1822. [cited by applicant]
clinicaltrials.gov, (Dec. 18, 2019) “GEN1042 Safety Trial and Anti- tumor Activity in Participants with Malignant Solid Tumors”, History of Changes for Study: NCT04083599, ClinicalTrials.gov Identifier: NCT04083599, htt… [cited by applicant]
Dickopf et al., Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies, Comput. Struct. Biotechnol. J., May 14, 2020, 18: 1221-1227. [cited by applicant]
Etxeberria et al., New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis, ESMO Open Cancer Horizons, Jul. 2020, 4(Suppl. 3): e000733. [cited by applicant]
EU Clinical Trials Register, “A Phase 2, multicenter, randomized, open-label trial of GEN1046 as monotherapy and in combination with Pembrolizumab in subjects with relapsed/refractory metastatic non-small cell lung canc… [cited by applicant]
Hirano et al., “CD27 synergizes with CD40 to induce IgM, IgG, and IgA antibody responses of peripheral blood B cells in the presence of IL-2 and IL-10”, Immunol. Letters, Oct. 31, 2003, 89(2-3): 251-257. [cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/EP2016/050308, mailed Jun. 8, 2016. [cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/EP2022/056021, mailed Jun. 24, 2022. [cited by applicant]
Labrijn et al., Controlled Fab-arm exchange for the generation of stable bispecific IgG1, Oct. 2014, Nature Protocols, 9(10): 2450-2463. Epub Sep. 25, 2014. [cited by applicant]
Lee et al., Novel antibodies targeting immune regulatory checkpoints for cancer therapy, British Journal of Clinical Pharmacology, May 23, 2013, 76(2): 233-247. [cited by applicant]
Muik et al., “DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity”, J. Immunother. Cancer, Jun. 10, 2022, 10(6): e004322. [cited by applicant]
Muller et al., Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization, FEBS Journal, May 2008, 275(9): 2296-2304. Epub Apr. 3, 2008. [cited by applicant]
Nie et al., Biology drives the discovery of bispecific antibodies as innovative therapeutics, Antibody Therapeutics, Feb. 17, 2020, 3(1): 18-62. [cited by applicant]
Poh, “Dual-targeting approach for CD40 and 4-1BB,” Cancer Discovery, Jan. 2, 2022, 12(1): 9-10. [cited by applicant]
Tamura et al., Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only, J. Immu… [cited by applicant]
Vink et al., A simple, robust and highly efficient transient expression system for producing antibodies, Methods, Jan. 1, 2014, 65(1): 5-10. Epub Jul. 17, 2013. [cited by applicant]
Vonderheide, CD40 Agonist Antibodies in Cancer Immunotherapy, Annual Review of Medicine, Jan. 27, 2020, 71: 47-58. Epub Aug. 14, 2019. [cited by applicant]
Weiner et al., Antibody-Based Immunotherapy of Cancer, Cell, Mar. 16, 2012, 148(6): 1081-1084. [cited by applicant]
Xiong, Research Advances of Molecular Structure of Tumor Necrosis Factor Superfamily, Medical Recapitulate, 2011, 17(22): 3407-3409. [cited by applicant]
You et al., Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies, Vaccines, Jul. 2, 2021, 9(7): 724. [cited by applicant]
Zheng et al., Expression Improvement and Mechanistic Study of the Retro-Diels-Alderase Catalytic Antibody 10F11 by Site-directed Mutagenesis, J. Mol. Biol., Aug. 13, 2004, 341(3): 807-814. [cited by applicant]
Abdiche et al., “Antibodies Targeting Closely Adjacent or Minimally Overlapping Epitopes Can Displace One Another”, PLoS One, Jan. 6, 2017, 12(1): e0169535. [cited by applicant]
Abiko et al., “IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer”, Br. J. Cancer, Mar. 31, 2015, 112(9): 1501-1509. [cited by applicant]
Aix et al., “Peripheral and tumoral immune activity in the expansion part of the first-in-human Duobody®-pd-l1x4-1bb (GEN1046) tria”, Journal for Immunotherapy of Cancer, Nov. 2021, 9(2 Suppl.): A546. [cited by applicant]
Al-Lazikani et al., “Standard conformations for the canonical structures of immunoglobulins”, J. Mol. Biol., Nov. 7, 1997, 273(4): 927-948. [cited by applicant]
Almagro et al., “Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy”, Frontiers in Immunology, Jan. 4, 2018, 8: 1751. [cited by applicant]
Aslanidis et al. “Ligation-independent cloning of PCR products (LIC-PCR)”, Nucleic Acids Res., Oct. 25, 1990, 18(20): 6069-6074. [cited by applicant]
Azuma et al., “B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells”, Blood, Apr. 1, 2008, 111(7): 3635-3643. Epub Jan. 25, 2008. [cited by applicant]
Baek et al., “Effects of Histidine and Sucrose on the Biophysical Properties of a Monoclonal Antibody”, Pharm Res., Mar. 2017, 34(3): 629-639. [cited by applicant]
Barbas et al., “Molecular Profile of an Antibody Response to HIV-1 as Probed by Combinatorial Libraries”, J. Mol. Biol., Apr. 5, 1993, 230(3): 812-823. [cited by applicant]
Bartkowiak et al., “4-1BB agonists: multi-potent potentiators of tumor immunity”, Frontiers in Oncology, Jun. 8, 2015, 5: 117. [cited by applicant]
Bebbington et al., “High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker”, Biotechnology, Feb. 1992, 10(2): 169-175. [cited by applicant]
Benvenisty et al., “Direct introduction of genes into rats and expression of the genes”, PNAS USA, Dec. 1986, 83(24): 9551-9555. [cited by applicant]
Berge et al., “Pharmaceutical salts”, J. Pharm. Sci., Jan. 1977, 66(1): 1-19. [cited by applicant]
Bird et al., “Single-Chain Antigen-Binding Proteins”, Science, Oct. 21, 1988, 242(4877): 423-426. [cited by applicant]
Bitter et al., “Expression and secretion vectors for yeast”, Methods Enzymol., 1987, 153: 516-544. [cited by applicant]
Blankenship et al., “Abstract #5465: CD79BxDR SCORPIONTM molecule: a single chain, bispecific immunotherapeutic with potent in vitro activity against B cell lymphoma”, Cancer Res., May 1, 2009, 69(9 Suppl.): 5465. [cited by applicant]
Bleeker et al., “Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect”, Blood, Nov. 15, 2001, 98(10): 3136-314… [cited by applicant]
Bodmer et al., “The molecular architecture of the TNF superfamily”, Trends Biochem. Sci., Jan. 2002, 27(1): 19-26. [cited by applicant]
Boland et al., “A National Cancer Institute Workshop on Microsatellite Instability for Cancer Detection and Familial Predisposition: Development of International Criteria for the Determination of Microsatellite Instabil… [cited by applicant]
Bostrom et al., “Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site”, Science, Mar. 20, 2009, 323(5921): 1610-1614. [cited by applicant]
Brahmer et al., “Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates”, J. Clin. Oncol., Jul. 1, 2010, 28(1… [cited by applicant]
Brochet et al., “IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis”, Nucleic Acid Research, Jul. 1, 2008, 36: W503-W508. Epub May 24, 2008. [cited by applicant]
Bruhns et al., “Specificity and affinity of human Fcg receptors and their polymorphic variants for human IgG subclasses”, Blood, Apr. 16, 2009, 113(16): 3716-3725. Epub Nov. 18, 2008. [cited by applicant]
Bryson et al., “Prediction of immunogenicity of therapeutic proteins: validity of computational tools”, BioDrugs, Feb. 1, 2010, 24(1): 1-8. [cited by applicant]
Buchan et al., “PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell-Driven Antitumor Immunity”, Clinical Cancer Research, Mar. 7, 2018: 24(10): 2383-2394,. [cited by applicant]
Butte et al., “Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses”, Immunity, Jul. 2007, 27(1): 111-122. Epub Jul. 12, 2007. [cited by applicant]
Calvo et al., “Interim results of a phase 1/2 study of JNJ-63723283, an anti-PD-1 monoclonal antibody, in patients with advanced cancers”, Journal of Clinical Oncology, 2018 ASCO-SITC Clinical Immuno-Oncology Symposium,… [cited by applicant]
Chen et al., “Combination of 4-1BB 1-101 Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model”, Cancer Immunol. Res., Feb. 2015, 3(2):149-160. Epub Nov. 11, 2014. [cited by applicant]
Chen et al., “Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations”, The EMBO Journal, 1995, 14(12): 2784-2794. [cited by applicant]
Chiu et al., “Antibody Structure and Function: The Basis for Engineering Therapeutics”, Antibodies (Basel), Dec. 3, 2019, 8(4): 55. [cited by applicant]
Christiansen et al., (2011) “Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies”, Proceedings of the National Academy of Sciences, 108(10):4141-4146. [cited by applicant]
clinicaltrials.gov, “A Study of ES101 (PD-L1 x4-1 BB Bispecific Antibody) in Patients with Advanced Solid Tumors”, ClinicalTrials.gov ID: NCT04009460, Jul. 5, 2019. [cited by applicant]
clinicaltrials.gov, (Dec. 23, 2021) “Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer”, Study Details, ClinicalTrials.go… [cited by applicant]
clinicaltrials.gov, (May 14, 2019) “GEN1046 Safety Trial in Patients With Malignant Solid Tumors”, Study Details, ClinicalTrials.gov Identifier: NCT03917381, https://clinicaltrials.gov/study/NCT03917381. [cited by applicant]
clinicaltrials.gov, (Oct. 22, 2024) “Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer”, Study Details, ClinicalTrials.go… [cited by applicant]
Corsaro et al., “Enhancing the efficiency of DNA-mediated gene transfer in mammalian cells”, Somatic Cell Genet., Sep. 1981, 7(5): 603-611. [cited by applicant]
Crowe et al., “Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary c… [cited by applicant]
D'Angelo et al., “Many Routes to an Antibody Heavy-Chain CDR3: Necessary, Yet Insufficient, for Specific Binding,” Frontiers in Immunology, vol. 9, Article 395 Mar. 2018; (Year: 2018). [cited by applicant]
Dall'Acqua et al., “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)”, J. Biol. Chem., Aug. 18, 2006, 281(33): 23514-23524. Epub Jun. 2, 2006. [cited by applicant]
De Keersmaecker et al., “The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses”, J. Leukoc. Biol., Jun. 2011, 89(6): 989-999. Epub Mar. 22, 2011. [cited by applicant]
Deo et al., “Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood”, J. Immunol., Feb. 15, 1998, 1… [cited by applicant]
Dick et al., “C-terminal lysine variants in fully human monoclonal antibodies: investigation of test methods and possible causes”, Biotechnol. Bioeng., Aug. 15, 2008, 100(6): 1132-1143. [cited by applicant]
Dimasi et al., “The Design and Characterization of Oligospecific Antibodies for Simultaneous Targeting of Multiple Disease Mediators”, J. Mol. Biol., Oct. 30, 2009, 393(3): 672-692. Epub Aug. 20, 2009. [cited by applicant]
Dong et al., “Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion”, Nat. Med., Aug. 2002, 8(8): 793-800. Epub Jun. 24, 2002. [cited by applicant]
Doppalapudi et al., “Chemically programmed antibodies: Endothelin receptor targeting CovX-Bodies”, Bioorg. Med. Chem. Lett., Jan. 15, 2007, 17(2): 501-506. Epub Oct. 7, 2006. [cited by applicant]
Edelman et al., “The covalent structure of an entire gammaG immunoglobulin molecule”, PNAS USA, May 1969, 63(1): 78-85. [cited by applicant]
Ehrenmann et al., “IMGT/3Dstructure-DB and IMGT/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF”, Nucleic Acids Res., Jan. 2010, 38: D301-D307. Epub Nov. 9,… [cited by applicant]
Eisenhauer et al., “New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)”, Eur. J. Cancer, Jan. 2009, 45(2): 228-247. [cited by applicant]
El-Khoueiry et al., “Novel Intratumoral Agent, Int230-6 Induces Cancer Cell Death, Increases Tumor Infiltrates And Results In Durable Benefit Alone Or In Combina”, J. Immunother. Cancer, Nov. 2020, 8(Suppl. 3): A250-A25… [cited by applicant]
Fisher et al., “Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity”, 2012 61: 1721-17333. [cited by applicant]
Foster et al., “Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors”, Clin Cancer Res., Oct. 15, 2021, 27(20): 5510-5518. Epub Jun. 24, 2021. [cited by applicant]
Francisco et al., “PD-L1 regulates the development, maintenance, and function of induced regulatory T cells”, J. Exp. Med., Dec. 21, 2009, 206(13): 3015-3029. Epub Dec. 14, 2009. [cited by applicant]
Garralda et al., “First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1x4-1BB (GEN1046) in patients with advanced solid tumors”, J. Immunother. Cancer, Nov. 2020, 8(Supp… [cited by applicant]
Gershoni et al., “Epitope mapping—The first step in developing epitope-based vaccines”, BIOD, Jan. 2007, 21(3): 145-156. [cited by applicant]
Geuijen et al., “A human 1-101 CD137xPD-Li bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade”, Nat. Commun., Jul. 21, 2021, 12(1): 4445. [cited by applicant]
Gilson et al., “Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA)”, Cancers (Basel), Mar. 24, 2021, 13(7): 1491. [cited by applicant]
Giusti et al., “Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region”, PNAS USA, May 1987, 84(9): 2926-2930. [cited by applicant]
Gopal et al., “First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas”, Clinical Cancer Research, Jun. 1, 2020, 26(11):… [cited by applicant]
Gray et al., (2008) “Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies”, European Journal of Immunology, 38(9):2499-2511. [cited by applicant]
Gros et al., PD-1 identifies the patient-specific CD8+ tumor reactive repertoire infiltrating human tumors J. Clin Invest 2014;124(5):2246-59. [cited by applicant]
Gulley et al., “Infusion-related reactions with administration of avelumab: mild and manageable side effects”, Translational Cancer Research, Oct. 2017, 6(Suppl 7): S1296-S1298. [cited by applicant]
Han et al., “The distinct clinical trajectory, metastatic sites, and immunobiology of microsatellite-instability-high cancers”, Frontiers in Genetics, Dec. 1, 2022, 13: 933475. [cited by applicant]
Hanahan et al., “Hallmarks of cancer: the next generation”, Cell, Mar. 4, 2011, 144(5): 646-674. [cited by applicant]
Hardy et al., “A Monoclonal Antibody against a Human B Lymphoblastoid Cell Line Induces Tumor Regression in Mice”, Cancer Research, Nov. 15, 1994, 54(22): 5793-5796. [cited by applicant]
Haynes et al., (2008) “Immunogenic anti-cancer chemotherapy as an emerging concept”, Current Opinion in Immunology, 20(5):545-557. [cited by applicant]
Heery et. al., “Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase Ia, multicohort, dose-escalation trial”, Lancet Oncology, Mar. 31, 2017, 18(5): 587-598. [cited by applicant]
Hinton et al., “An engineered human IgG1 antibody with longer serum half-life”, J. Immunol., Jan. 1, 2006, 176(1): 346-356. [cited by applicant]
Hirano et al., “Blockade of B7-Hi 1-101 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity”, Cancer Research, Feb. 1, 2005, 65(3): 1089-1096. [cited by applicant]
Hmila et al., “A bispecfic nanobody to provide full protection against lethal scorpion envenoming”, FASEB Journal, Sep. 2010, 24(9): 3479-3489. Epub Apr. 21, 2010. [cited by applicant]
Holt et al., “Domain antibodies: proteins for therapy”, Trends in Biotechnology, Nov. 2003, 21(11), 484-490. [cited by applicant]
Honegger et al., “Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool”, J. Mol. Biol., Jun. 8, 2001, 309(3): 657-670. [cited by applicant]
Horn et al., “CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1 tumor cells, and extends the survival of tumor-bearing humanized mice”, Oncotarget, Aug. 29, 2017, 8(35… [cited by applicant]
Huang et al., “Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma”, Clinical Cancer Research, Mar. 15, 2018, 24(6): 1296-1304. Epub Jan. 22, 2018. [cited by applicant]